Back to search results

Lisinopril for Polycythemia Study

This study is testing if a medication called Lisinopril can help people with polycythemia (a condition where you have too many red blood cells). Researchers want to see if Lisinopril can lower levels of hemoglobin (a protein in red blood cells), hematocrit (the percentage of red blood cells in your blood), and erythropoietin (a hormone that tells your body to make red blood cells). You might be able to join if you are between 18 and 80 years old and have high hemoglobin levels, but not if you have a specific genetic mutation (JAK2) or are a current or recent heavy smoker. The study is looking for 30 participants, but its current status is unclear.

Study design
This is an interventional study involving 30 participants. Participants will receive increasing doses of Lisinopril over 12 weeks.
What's involved
You would take Lisinopril tablets daily, starting at 2.5 mg and increasing to 10 mg over 12 weeks. Blood tests will be done at baseline and on specific days during the study.
Compensation
Not stated in the trial record.
Follow-up
Your hemoglobin, hematocrit, and erythropoietin levels will be measured at baseline and on study days 3, 5, and 7.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07594535

The Effect Of Lisinopril On Polycythemia

Recruiting
PHASE4Ages 18–80InterventionalTreatment
Mayo Clinic
~30 participants
Updated 2026-08-21 on ClinicalTrials.gov
What's tested:Lisinopril Tablets

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in hemoglobin
Measured over Baseline (dose 0), study day 3 (dose 2.5), study day 5 (dose 5.0), and study day 7 (dose 10.0)
+2 more outcomes measured

Conditions

Polycythemia

Explore related trials

Polycythemia

Where it's being run

2 sites across 1 states
Minnesota2

Study leadership

  • Michael Joyner, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Nancy Meyer
[email protected]
507-255-0913
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Hemoglobin in Men: \>16.5 g/dL (10.3 mmol/L).
Hemoglobin in Women \>16.0 g/dL (10.0 mmol/L).
BMI 18-40 kg/m2.

Exclusion

Positive JAK2 gene linked to Polycythemia Vera.
Current smoker or previous heavy smoker (\>15 pack years) who quit less than 12 months prior to enrollment.
Resting SpO₂ ≤ 94% on room air.
Current or recent (within the past 6 months) use of testosterone or androgen supplementation.
Any confounding respiratory or renal disease, including diagnosed or suspected sleep apnea, or stage 3 and up of chronic kidney disease.
Any confounding hematologic disease that may alter hemoglobin level.
Currently treated with ACE inhibitors.
Currently treated with potassium-sparing diuretics.
Currently on SGLT2 or use within 4 weeks prior to screening.
Baseline systolic blood pressure ≤90 mmHg.
Baseline systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg.
Occupational exposure associated with chronically elevated COHb (auto repair, etc.).
History of anaphylaxis or angioedema.
Pregnant or breastfeeding.

What this trial measures

  • Change in hemoglobinBaseline (dose 0), study day 3 (dose 2.5), study day 5 (dose 5.0), and study day 7 (dose 10.0)

    Hemoglobin measures the amount of a protein in red blood cells via blood sample and is reported in grams per deciliter (g/DL) Hemoglobin (Hb) concentration exceeding 16 g/dL in women and 16.5 g/dL in men is considered abnormal.

  • Change in hematocritBaseline (dose 0), study day 3 (dose 2.5), study day 5 (dose 5.0), and study day 7 (dose 10.0)

    Hematocrit (Hct) is measured by determining the percentage of red blood cells (RBCs) in a blood sample. Hematocrit (Hct) ≥ 48% in women and ≥49% in men is considered elevated.

  • Change in erythropoietinBaseline (dose 0), study day 3 (dose 2.5), study day 5 (dose 5.0), and study day 7 (dose 10.0)

    Erythropoietin is measured via blood test to detect hormone levels, and is reported in milliunits per milliliter (mU/mL). A normal reference range is generally 4 to 26 mU/mL)